Top

Published in:

01-06-2013 | Original Communication

Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study

Authors: Roberto D’Alessandro, Luca Vignatelli, Alessandra Lugaresi, Elisa Baldin, Franco Granella, Maria Rosaria Tola, Susanna Malagù, Luisa Motti, Walter Neri, Massimo Galeotti, Mario Santangelo, Laila Fiorani, Enrico Montanari, Cinzia Scandellari, Maria Donata Benedetti, Maurizio Leone

Published in: Journal of Neurology | Issue 6/2013

Abstract

The aim of the study was to estimate the rate of conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) and to investigate variables predicting conversion in a cohort of patients presenting with symptoms suggestive of MS. Patients with a first symptom suggestive of MS in the preceding 6 months and exclusion of other diseases were enrolled in an observational prospective study from December 2004 through June 2007. Conversion from CIS to MS according to both McDonald and Clinically Defined Multiple Sclerosis (CDMS) criteria was prospectively recorded until March 2010. The multivariate Cox proportional hazard model was used to assess the best predictive factors of conversion from CIS to MS. Among 168 patients included in the analysis, 122 converted to MS according to McDonald criteria whereas 81 converted to MS according to CDMS criteria. The 2-year probability of conversion was 57 % for McDonald Criteria and 36 % for CDMS criteria. Variables at enrolment significantly associated with conversion according to McDonald criteria were age and positivity for Barkhof criteria, and according to Poser’s CDMS criteria, age, positivity for Barkhof criteria and no disease modifying therapy. In this large prospective cohort study the conversion rate from CIS to MS in patients presenting with recent symptoms suggestive of MS was within the range of previous observational studies and lower than that reported in the placebo arm of randomized trials. We confirm the prognostic value of MRI in addition to the previous experimental data on the protective role of disease-modifying therapies.

Available only for authorised users

Sastre-Garriga J, Tintore M, Rovira A et al (2003) Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. Mult Scler 9(1):39–43PubMedCrossRef

Miller D, Barkhof F, Montalban X et al (2005) Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 4(5):281–288PubMedCrossRef

Beck RW, Chandler DL, Cole SR et al (2002) Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 51(4):481–490PubMedCrossRef

Poser CM, Paty DW, Scheinberg L et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227–231PubMedCrossRef

Tintore M, Rovira A, Arrambide G et al (2010) Brainstem lesions in clinically isolated syndromes. Neurology 75(21):1933–1938PubMedCrossRef

Paolino E, Fainardi E, Ruppi P et al (1996) A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. J Neurol Neurosurg Psychiatry 60(5):572–575PubMedCrossRef

Sormani MP, Tintore M, Rovaris M et al (2008) Will Rogers phenomenon in multiple sclerosis. Ann Neurol 64(4):428–433PubMedCrossRef

Morrissey SP, Miller DH, Kendall BE et al (1993) The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 116(Pt 1):135–146PubMedCrossRef

Comi G, Filippi M, Barkhof F et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268):1576–1582PubMedCrossRef

10.

Kappos L, Polman CH, Freedman MS et al (2006) Treatment with interferon β-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67(7):1242–1249PubMedCrossRef

11.

Comi G, De Stefano N, Freedman MS, et al (2012) Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 11(1):33–41

12.

Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374(9700):1503–1511PubMedCrossRef

13.

Rojas JI, Patrucco L, Cristiano E (2010) Oligoclonal bands and MRI in Clinically Isolated Syndromes: predicting conversion time to multiple sclerosis. J Neurol 257(7):1188–1191CrossRef

14.

Korteweg T, Tintore M, Uitdehaag B et al (2006) MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 5(3):221–227PubMedCrossRef

15.

Chard DT, Dalton CM, Swanton J et al (2011) MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 82(2):176–179PubMedCrossRef

16.

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452PubMedCrossRef

17.

Fischer JS, Rudick RA, Cutter GR et al (1999) The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 5(4):244–250PubMed

18.

Solari A, Radice D, Manneschi L et al (2005) The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci 228(1):71–74PubMedCrossRef

19.

Kalkers NF, Bergers L, de Groot V et al (2001) Concurrent validity of the MS Functional Composite using MRI as a biological disease marker. Neurology 56(2):215–219PubMedCrossRef

20.

McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127PubMedCrossRef

21.

Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58(6):840–846PubMedCrossRef

22.

Barkhof F, Filippi M, Miller DH et al (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120(Pt 11):2059–2069PubMedCrossRef

23.

Tintore M, Rovira A, Martinez MJ et al (2000) Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 21(4):702–706PubMed

24.

Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302PubMedCrossRef

25.

Rocca MA, Agosta F, Sormani MP et al (2008) A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol 255(5):683–691PubMedCrossRef

26.

McAlpine D (1972) Multiple sclerosis: a re-appraisal. In: Acheson ED (ed) McAlpine D LC. The problem of diagnosis. Churchill Livingstone, Edinburgh, pp 142–178

27.

Tintoré M, Rovira A, Río J (2006) Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 67:968–972PubMedCrossRef

28.

Feuillet L, Reuter F, Audoin B et al (2007) Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 13(1):124–127PubMedCrossRef

29.

Mattarozzi K, Vignatelli L, Baldin E et al (2012) Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study. Int J Clin Pract 66(5):504–514PubMedCrossRef

Title: Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study
Authors: Roberto D’Alessandro
Luca Vignatelli
Alessandra Lugaresi
Elisa Baldin
Franco Granella
Maria Rosaria Tola
Susanna Malagù
Luisa Motti
Walter Neri
Massimo Galeotti
Mario Santangelo
Laila Fiorani
Enrico Montanari
Cinzia Scandellari
Maria Donata Benedetti
Maurizio Leone
Publication date: 01-06-2013
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue 6/2013
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-013-6838-x

At a glance: The STEP trials

Springer Medicine

Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2013

Thank you Jan van Gijn

Muscle MRI in severe Guillain–Barré syndrome with motor nerve inexcitability

Isolated floccular infarction: impaired vestibular responses to horizontal head impulse

Assessment of long-term outcome in neurological disease

Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway

A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene